Background
==========

Hip osteoarthritis (OA), with a prevalence of approximately of 1.1% for elderly men and 3.6% for elderly women, greatly affects their daily activity and quality of life by causing joint pain and stiffness \[[@b1-medscimonit-25-6436]\].

The pathogenesis of hip OA is characterized by femoroacetabular degeneration, with chronic wearing of cartilage tissue during the inflammatory process \[[@b2-medscimonit-25-6436]\]. The rate of response to conventional pharmacologic therapy is mostly limited, and then total hip replacements (THR) might be indicated. For large populations waiting for or unwilling to undergo surgical treatment, a more effective adjunct therapy is still needed \[[@b3-medscimonit-25-6436]\].

With restoration of the protective viscoelasticity of synovial fluid, intra-articular (IA) viscosupplementation (VS) with use of hyaluronic acid (HA) solution effectively reduces friction and improves mobility in OA patients \[[@b4-medscimonit-25-6436],[@b5-medscimonit-25-6436]\].

However, there is little published data on the efficacy of VS for hip OA, especially from large-scale randomized controlled trials (RCTs) with validated methodological quality, and the results have been conflicting. A previous meta-analysis showed a statistically significant difference in visual analogue scale (VAS) using VS in hip OA, but the conclusions were mainly based on a large proportion of poorly-designed cohort or uncontrolled studies, which only allowed for limited interpretation \[[@b6-medscimonit-25-6436]\]. Another recent systematic review and meta-analysis showed little evidence of VS efficacy in pain relief at 3 months, but they failed to perform a pooled analysis, and the functional score was not reported \[[@b7-medscimonit-25-6436]\].

Unanswered questions on this topic include the followings: Is VS superior to placebo in reducing hip OA pain? How fast does VS act and how long is it still effective? What are the potential adverse effects? Therefore, we performed the present meta-analysis with high-quality RCTs, comparing efficacy between VS and placebo for hip OA. Subgroup analysis at different time windows was also carried out by meta-analysis, and we summarized the safety profiles of the interventions as well.

Material and Methods
====================

Literature search
-----------------

Two authors (Lin and Liao) independently searched Medline, Clinical Trial Register Center, EMBASE, and Cochrane databases without limits up to January 26, 2019. We used: "(hyaluronan OR hyaluronic acid OR viscosupplementation) AND Hip osteoarthritis" as terms and Boolean operators. All searches were limited to human randomized clinical trials reported in journals, with no language restrictions.

Inclusion and exclusion criteria
--------------------------------

The studies were included in which: (a) the trials were RCTs, (b) the target population were adults with primary hip OA defined according to the American College of Rheumatology (ACR) criteria and/or radiographic changes, and (c) the trials at least performed 1 comparison of VS versus placebo control. The studies were excluded if they were: (a) not for hip OA patients, (b) clinical study design or protocol, cohort or non-controlled studies, case series, and reviews, and (c) only abstracts. Any disagreements among authors were resolved by discussion.

Quality evaluation
------------------

The methodological validity of included studies was evaluated independently by 2 authors (Liao and Lin) using a tool for assessment of risk of bias, which primarily comprised 6 specific contents, including randomization schedule, allocation concealment, double-blinding, data completeness, and selective outcome \[[@b8-medscimonit-25-6436]\]. Means of κ test were used to assess disagreements, which were resolved by discussion of the 2 reviewers (Liao and Lin).

Data extraction, imputation, and analysis
-----------------------------------------

Two reviewers (Zhu and Shi) seperately abstracted the useful outcome data and confirmed the precision. In each included study, the study design, number of patients, demographic data (age and sex), OA severity, inclusion criteria, intervention protocol, guidance of injections, duration of follow-up, loss to follow-up, outcome measurement, and co-interventions, were extracted and summarized. When possible, we sent emails to the corresponding author of each included article to check the appropriateness of the extracted outcome and the quality evaluation.

The pain scores of patients after treatments were the main outcome. We used endpoint data rather than change data to maximize data availability. When an article provided data on more than 1 pain scale, we referred to a previously described hierarchy of pain-related outcomes and extracted the outcome that was highest on this list \[[@b9-medscimonit-25-6436]\]. Global pain took precedence over pain on walking and pain subscales on the Western Ontario and McMaster Universities arthritis index (WOMAC). If a trial provided data on both -- for example, global pain scores and WOMAC pain subscores -- we recorded only data on global pain scores. If the outcome data were not available in tables or text, we measured and calculated them from figures of the original article. If standard deviations (SDs) were not provided, we calculated them from standard errors or confidence intervals, as described elsewhere \[[@b10-medscimonit-25-6436]\]. Moreover, WOMAC function score or Lequesne index was used for the pooled analysis of functional outcomes, and we summarized the safety profile whenever available.

Since the treatment duration and the post-treatment assessment time points varied among the trials, we grouped the time points of outcome assessments of individual trials into 3 intervals: 7 to 14 days, 28 to 30 days, and 56 to 182 days (at final visit). If more than 1 time point was reported in a window, we extracted the data nearest to the latest follow-up time within the window. This grouping was made to make maximum use of all available data and to assess the persistence of treatment effects from different time points.

The pain and function scores at different time intervals were converted to standardized mean differences (SMD) using Review Manager 5.2 software. This ensured comparability between different outcomes assessed with different instruments, with effect sizes expressed in common units (i.e., SD). A negative effect size indicates a benefit of the VS intervention. Sensitivity analysis was conducted in STATA 11.

The statistical heterogeneity was evaluated by a χ^2^ test on N-1 degree of freedom (p\<0.1 indicated significance). The formula \[(Q--df)/Q\]×100% (Q: the χ^2^ statistic; df: degree of freedom) was used to calculate the inconsistency I^2^, which represented the ratio of the consistency in effect size due to variation among the included studies. A I^2^ value over 50% indicated significant inconsistency and we used the random-effects model to combine data from different studies; otherwise, we used the fixed-effects model \[[@b8-medscimonit-25-6436]\].

We performed sensitivity analysis to test the stability of our main outcomes by omitting one single trial each time (only 5 studies were analyzed). Funnel plot analysis and meta-regression analysis could not be performed due to the insufficient number of studies included.

Results
=======

Selection of studies
--------------------

The initial literature research found 86 relevant studies, of which 58 were excluded after eliminating duplicate studies or due to inappropriateness based on titles, and a further 22 studies were excluded after reading the abstracts. In total, 80 studies were excluded. Of the remaining 6 studies, 1 reported a dichotomous outcome for pain relief and it was excluded \[[@b11-medscimonit-25-6436]\]. In a study by Migliore et al., local anesthesia with mepivacaine was administrated to the placebo group \[[@b12-medscimonit-25-6436]\]. Because the effects of local anesthetics only persisted for a few hours, the study was included after discussion. Overall, as presented in [Figure 1](#f1-medscimonit-25-6436){ref-type="fig"}, there were 5 RCTs with 591 patients included in our meta-analysis \[[@b12-medscimonit-25-6436]--[@b16-medscimonit-25-6436]\].

Information of included studies
-------------------------------

The main data from the 5 included trials are summarized in [Table 1](#t1-medscimonit-25-6436){ref-type="table"}. All the studies were designed as placebo-applied RCTs, of which 3 studies directly compared the HA to a placebo control group \[[@b12-medscimonit-25-6436],[@b14-medscimonit-25-6436],[@b16-medscimonit-25-6436]\], and the other 2 were multi-armed studies, both using HA, steroid, and placebo groups \[[@b13-medscimonit-25-6436],[@b15-medscimonit-25-6436]\]. Fluoroscopic guidance or ultrasound guidance was used to assist IA injection in all studies. Only aged adults (mean age range: 60.2--70 years) with symptomatic primary hip OA were included in all of the studies. The weighted kappa value for the consistency on inclusion between the 2 authors was 0.85 (95% CI: 0.76--0.94).

Methodological quality
----------------------

The methodological validity was assessed independently by 2 authors (Lin and Liao). The randomization schedule was based on randomly permuted blocks in 1 study \[[@b13-medscimonit-25-6436]\], and its allocation concealment was not explicitly stated, while the other 4 studies \[[@b12-medscimonit-25-6436],[@b14-medscimonit-25-6436]--[@b16-medscimonit-25-6436]\] had adequate computer-generated sequences and detailed allocation concealment. Intention-to-treat (ITT) analysis was clearly applied in 4 studies \[[@b13-medscimonit-25-6436]--[@b16-medscimonit-25-6436]\], and selective reporting was not found in any of the studies. Overall, the 5 studies used adequate blinding and reported the details of loss to follow-up ([Table 2](#t2-medscimonit-25-6436){ref-type="table"}). The weighted kappa value for consistency of methodological validity between the 2 authors was 0.88 (95% CI: 0.79--0.97).

Efficacy of measurement for pain relief after injection
-------------------------------------------------------

Most trials demonstrated relief in pain in both the VS and placebo groups at different time intervals compared to baseline ([Table 3](#t3-medscimonit-25-6436){ref-type="table"}). Specifically, VS showed a more dramatic pain reduction compared to baseline in 3 studies \[[@b12-medscimonit-25-6436],[@b13-medscimonit-25-6436],[@b16-medscimonit-25-6436]\], even at the final visit (Brander et al: −34.4%, p\<0.001; Migliore et al: −29.7%, p\<0.01; and Qvistgaard et al., −22.4%, p\<0.05). However, only in Migliore et al. did the VS group still have better pain relief than the placebo group (−29.7% versus −16.7%, p\<0.05). No difference between the 2 groups was reported in the other studies. In addition, neither the VS group nor the placebo group had obvious pain alleviation compared to baseline in 2 studies \[[@b14-medscimonit-25-6436],[@b15-medscimonit-25-6436]\].

The pooled analysis confirmed the above results, showing that VS probably was not significantly more effective than placebo control during any time window \[7--14 days: 3 studies, SMD (95% CI): −0.18 (−0.47, 0.10), p=0.21, I^2^=0%; 28--30 days: 4 studies, SMD (95% CI): 0.02 (−0.15, 0.19), p=0.82, I^2^=31%; at final visit: 5 studies, SMD (95% CI): −0.14 (−0.46, 0.18), p=0.38, I^2^=63%, [Figure 2](#f2-medscimonit-25-6436){ref-type="fig"}\].

Efficacy of measurement for function improvement after injection
----------------------------------------------------------------

Similarly, there was significant improvement in function scores in the VS group compared to baseline in 2 studies \[[@b12-medscimonit-25-6436],[@b16-medscimonit-25-6436]\], but not in the other studies \[[@b13-medscimonit-25-6436]--[@b15-medscimonit-25-6436]\] ([Table 4](#t4-medscimonit-25-6436){ref-type="table"}). Not surprisingly, our meta-analysis shows the function scores did not differ between the VS and placebo groups at any time points \[7--14 days: 2 studies, SMD (95% CI): −0.14 (−0.52, 0.24), p=0.48, I^2^=0%; 28--30 days: 3 studies, SMD (95% CI): −0.16 (−0.34, 0.03), p=0.09, I^2^=45%; at final visit: 5 studies, SMD (95% CI): −0.28 (−0.60, 0.05), p=0.10, I^2^=63%, [Figure 3](#f3-medscimonit-25-6436){ref-type="fig"}\].

Heterogeneity and sensitivity analysis
--------------------------------------

Overall homogeneity among studies was observed in comparisons of pain and functional scores (7--14 days and 28--30 days); therefore, the pooled analysis was performed with fixed-effects models ([Figures 2](#f2-medscimonit-25-6436){ref-type="fig"}, [3](#f3-medscimonit-25-6436){ref-type="fig"}). When we detected substantial heterogeneity in comparisons of pain (I^2^=63%, p=0.03) and function (I^2^=63%, p=0.03) assessment at final visit, we used randomized-effects models to synthesize the results ([Figures 2](#f2-medscimonit-25-6436){ref-type="fig"}, [3](#f3-medscimonit-25-6436){ref-type="fig"}). For the main outcome -- pain score comparison at final visit between the 2 groups -- we carried out sensitivity analysis by omitting one single study each time to evaluate the stability of the results. By doing this analysis, we were also able to clarify the sources of heterogeneity. When omitting Atchia et al., the heterogeneity (I^2^=63%, p=0.03) was reduced to be minimal in the comparison (I^2^=0%, p=0.41, data not shown), indicating that study might be the main source of the heterogeneity. However, as shown in [Figure 4](#f4-medscimonit-25-6436){ref-type="fig"}, we did not observe any substantial alternation of overall results by deleting any single study.

Adverse events
--------------

IA treatment with fluoroscopic or ultrasound guidance seemed to be well tolerated and safe for hip OA patients. Infections were most concerning because the risk would be greatly increased by invasive procedures, particularly for deep joints. Confirmed infection was rather rare, and only 1 case in the VS group in Atchia et al. was reported \[[@b15-medscimonit-25-6436]\], and other rare adverse effects possibly related to the treatment (e.g., pruritus or hematoma at the injection area) were also only reported once in Richette et al., in 2 patients \[[@b14-medscimonit-25-6436]\]. The most common adverse effects were slight or moderate flare pain during or after injection: 4 patients of 19 in the VS groups in Atchia et al. \[[@b15-medscimonit-25-6436]\]; 1 of 21 in the placebo group and 3 of 101 in total in Qvistgaard et al. \[[@b13-medscimonit-25-6436]\]; 2 of 43 in the placebo group and 3 of 42 in the VS group in Richette et al. \[[@b14-medscimonit-25-6436]\]; and 4 of 172 in the placebo group and 12 of 182 in the VS group in Brander et al. \[[@b16-medscimonit-25-6436]\]. The pain was self-restricted and balanced in all injection groups. Withdrawals related to adverse events were reported only in Brander et al. \[[@b16-medscimonit-25-6436]\] (placebo: 10/172; VS: 10/182).

Discussion
==========

VS is believed to restore the rheological properties of synovial fluid by supplementing exogenous hyaluronic acid into painful joints, thereby increasing viscosity and generating analgesic, anti-inflammatory, and chondroprotective effects. However, contrary to the promising results of knee OA, we found that VS for hip OA did not achieve significant improvement in pain or function compared to a placebo control, which is consistent with a recent systematic review \[[@b7-medscimonit-25-6436]\]. However, the major limitation of this review was failure to perform a pooled analysis due to the heterogeneous design and varied outcome measurements among the included studies \[[@b7-medscimonit-25-6436]\].

A meta-analysis by Lieberman et al. \[[@b6-medscimonit-25-6436]\] showed that VS generated a minor but significant improvement over controls. However, the heterogeneous control groups (placebo, methylprednisolone, and other HA formulations) and the combined various time intervals (1--6 months) greatly hinder the interpretation of their results.

In our review, we exclusively targeted double-blind RCTs, 4 of which did report ITT data \[[@b13-medscimonit-25-6436]--[@b16-medscimonit-25-6436]\]. Only 1 trial did not use ITT methods, but it had low drop-out rates and satisfactory quality, and sensitivity analysis suggested it did not affect the overall results \[[@b12-medscimonit-25-6436]\].

In addition, we determined which measures to pool according to a hierarchy of recommended pain evaluations, and we converted the various outcome measures to standardized mean differences and successfully pooled effect sizes with unit-less measures of treatment efficacy. The quantitative results of our review then were highly informative in assessing the magnitude of therapeutic efficacy of VS. Furthermore, we examined the therapeutic response over time by separately pooling the data for each time interval. The outputs of this analysis elucidated the mode of therapeutic response attributable to VS intervention.

Our review strictly followed the instruction of the Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 \[[@b8-medscimonit-25-6436]\]. The detailed inclusion and exclusion criteria, the explicit demonstration of study selection and methodological quality assessment, and the quantitative analysis ensured the reproducibility of the methods. Selection bias was further avoided by elimination of duplicate studies.

In the present review, 3 of 5 studies showed that VS produced a dramatic pain reduction compared to baseline \[[@b12-medscimonit-25-6436],[@b13-medscimonit-25-6436],[@b16-medscimonit-25-6436]\]. Specifically, data from Brander et al. strongly suggested that VS significantly decreased pain scores compared to baseline during a 6-month follow-up after injection. These results were from a study with an adequate sample size (n=357), and the study was industry-sponsored, but they did not demonstrate the superiority of VS over placebo.

Our pooled analysis did not find differences between VS and placebo in pain or in function scores, which might be due to the small sample sizes of the included studies that failed to detect differences \[[@b17-medscimonit-25-6436]\]. However, the benefits of VS in hip OA was only demonstrated in open-label cohort studies, most of which included early OA \[[@b18-medscimonit-25-6436]--[@b21-medscimonit-25-6436]\].

A placebo, even normal saline, might appear to have a pain reduction effect due to the dilution of proinflammatory cytokines. For example, a recent meta-analysis by Zhang et al. found that IA placebo is efficacious for OA, especially for self-reported pain and function outcome measurements \[[@b22-medscimonit-25-6436]\].

The degree of radiographic severity of OA was reported to be strongly associated with the response to IA steroid injection of the hip, showing that more severe OA at baseline generally predicted less pain relief after IA injection \[[@b23-medscimonit-25-6436],[@b24-medscimonit-25-6436]\]. In our meta-analysis ([Table 1](#t1-medscimonit-25-6436){ref-type="table"}), 4 of 5 studies accounted for the majority of moderate-severity OA (over 50%) patients, which might have limited the response rate in the VS group \[[@b12-medscimonit-25-6436],[@b14-medscimonit-25-6436]--[@b16-medscimonit-25-6436]\]. Therefore, the strong placebo effects or the preponderance of moderate-severity cases might also explain the lack of statistical significance.

Our analysis has certain limitations that should be considered. (a) There was slight variability in the selection criteria of individual trials, including sex ratio and ages of patients. (b) Due to the insufficient number of trials, some relevant factors, such as the formulation of VS and the dose or number of injections, could not be analyzed. It has been reported that that higher viscosity and longer half-life result in better outcomes by increasing molecular weight of intra-articular hyaluronic acid \[[@b25-medscimonit-25-6436]\], but this is controversial. In the studies included in our review, 5 products were used, in which 2 (Durolane and Hylan G-F 20) \[[@b15-medscimonit-25-6436],[@b16-medscimonit-25-6436]\] have high molecular weights and the other 3 (Hyalubrix, Hyalgan, and Adant) have low-to-intermediate molecular weight \[[@b12-medscimonit-25-6436]--[@b14-medscimonit-25-6436]\] according to de Rezende et al. \[[@b26-medscimonit-25-6436]\]. Multiple injections (2 for Hyalubrix, 3 for Hyalgan) were generally used in low-to-intermediate molecular weight products, while Durolane and Hylan G-F 20 were injected only a single time according to their individual instructions, which could have reduced the discrepancy in their sustaining period among products with different molecular weights.

However, due to the complexity and chronic nature of OA, different phenotypes, long-term observation, and appropriate comparator should be fully considered in future RCTs; otherwise, there will still be a gap between recommendations from RCTs and clinical practice \[[@b27-medscimonit-25-6436]\]. We also agree that these influential factors should be further clarified by conducting subgroup analysis of a sufficient number of RCTs in future meta-analysis.

Our review shows that IA treatment with radiological guidance is well tolerated and safe for hip OA patients. Only 1 confirmed infection was reported in the VS group in Atchia et al. \[[@b15-medscimonit-25-6436]\]. The most common adverse effects were moderate pain during injection or lasting for a short time after injection, which were resolved without treatment. Whether pre-operated IA VS increases the risk of prosthetic infection after THR was not studied in this review, and whether the patients waiting for THR could receive IA VS remains unclear and should be carefully considered in future research.

Conclusions
===========

Our analysis was not able to show that IA VS reduces pain and improves function significantly better than placebo in a short-term follow-up. The benefits and safety of VS should be further assessed by sufficiently-sized, methodologically-sound studies with validated assessment of more clinically relevant end-points.

**Source of support:** The project was supported by the National Natural Science Foundation of China (81703017), by the Science and Technology Projects of Guangzhou, China (201804010080), and by the Science and Technology Projects of Huizhou, China (2018Y304)
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###### 

The overall information of the included trials.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ year/area         Sample size (VS/PLB)   Ages (mean+SD) and gender (Female/Male)   Moderate-severity OA[\*](#tfn2-medscimonit-25-6436){ref-type="table-fn"} (%)   Inclusion criteria                                                                       Injection                                                                                                                                         Guidance                Pain outcome extracted   Functional outcome extracted   Duration (days)   Co-factors                          Loss to follow-up (VS/PLB)
  ------------------------- ---------------------- ----------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ------------------------ ------------------------------ ----------------- ----------------------------------- ----------------------------
  Atchia/ 2011/ UK          58 (19/19)             69±8 (43/34)                              81%                                                                            1\. Aged over 50 years;\                                                                 Single injection. PLB: 3 ml NS; VS: 3ml Durolane                                                                                                  Ultrasound              Global pain (NRS)        WOMAC function subscale        56                NA                                  1/0 (5.3%/ 0)
                                                                                                                                                                            2. Primary unilateral hip OA;\                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                            3. Pain duration was more than a month or listed for elective THR                                                                                                                                                                                                                                                                                                                

  Brander/ 2018/ USA        357 (182/175)          60.3±9.4 (211/146)                        62%                                                                            1\. WOMAC score of 5 to 8\                                                               Single image-guided, VS: 6-mL injection of hylan G-F 20; PLB: 6 mL saline                                                                         Fuoroscopy/Ultrasound   WOMAC pain (NRS)         WOMAC function subscale        182               NA                                  3/3 (1.7%/ 1.7%)
                                                                                                                                                                            2. Age ≥35 years;\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                            3. Symptomatic hip OA (radiographically confirmed KL grade II or III per ACR criteria)                                                                                                                                                                                                                                                                                           

  Migliore/ 2009/ Italy     42 (22/20)             70±8.9                                    91%                                                                            1\. Age \>40 years;\                                                                     Two injections. VS: 60 mg Hyalubrix; Local analgesic 4 ml 2% Carbocaine                                                                           Ultrasound              Global pain (VAS)        Lequesne                       180               NA                                  5/3 (22.7%/15%)
                                                                                                                                                                            2. Ambulant without assistance;\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                            3. Hip OA by ACR; baseline VAS ≥4 cm;\                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                            4. Persistence of hip pain for at least 1 month before baseline                                                                                                                                                                                                                                                                                                                  

  Qvistgaard/2006/Denmark   69 (33/36)             66±12 (65/36)                             43%                                                                            1\. Aged above 18 years;\                                                                Three injections with 14 days interval. PLB: 2 ml NS; VS: 3 ml Hyalgan; Steroid: (One 1 ml/40 mg depome-drone, followed by two sham injections)   Ultrasound              Pain on walking          Lequesne                       90                1 mL of 1% lidocaine                5/3 (12%/8%)
                                                                                                                                                                            2. Hip OA as defined by the ACR criteria and radiographic changes;\                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                            3. Stable medication for at least 3 weeks before inclusion                                                                                                                                                                                                                                                                                                                       

  Richette/ 2009/ France    85 (42/43)             60.2±11.4 (50/35)                         65.40%                                                                         1\. Aged above 30 years;\                                                                Single injection: PLB: 2.5 ml NS; VS: 2.5 ml Adant                                                                                                Fuoroscopy              Global pain (VAS)        WOMAC function subscale        90                Treated with NSAIDs if necessary.   (6/4) (14.3%/9.3%)
                                                                                                                                                                            2. Hip OA as defined by the ACR criteria and radiographic changes;\                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                            3. Symptoms lasted for at least 1 month                                                                                                                                                                                                                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VS -- viscosupplementation; PLB -- placebo control; SD -- standard deviation; UK -- United Kindom; OA -- osteoarthritis; THR -- total hip replacement; NS -- saline water; NRS -- numerical rating scale (0--10); WOMAC -- Western Ontario and McMaster Universities Arthritis Index; ACR -- American College of Rheumatology radiographic criteria; VAS -- visual analogue scale; NA -- not available; NSAIDs -- non-steroidal antiinflammatory drugs.

Kellgren/Lawrence III/IV and radiographic grading (Croft) III/IV are considered as "moderate-severity" OA.

###### 

Quality assessment of the included trials.

  Study             Randomized adequately[\*](#tfn4-medscimonit-25-6436){ref-type="table-fn"}   Allocation concealed   Blinding[\*\*](#tfn5-medscimonit-25-6436){ref-type="table-fn"}   Selective reporting   Similar co-factors[\#](#tfn6-medscimonit-25-6436){ref-type="table-fn"}   (%) Loss to follow-up (VS/PLB)[\#\#](#tfn7-medscimonit-25-6436){ref-type="table-fn"}   ITT analysis
  ----------------- --------------------------------------------------------------------------- ---------------------- ---------------------------------------------------------------- --------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------------- --------------
  Atchia 2011       Adequately                                                                  Yes                    Double Blinded                                                   No                    Yes                                                                      5.3%/0                                                                                 Yes
  Brander 2018      Adequately                                                                  Yes                    Double Blinded                                                   No                    Yes                                                                      1.7%/1.7%                                                                              Yes
  Migliore 2009     Adequately                                                                  Unclear                Double Blinded                                                   No                    No                                                                       (22.7%/15%)                                                                            Unclear
  Qvistgaard 2006   Inadequately                                                                Unclear                Double Blinded                                                   No                    Yes                                                                      12%/8%                                                                                 Yes
  Richette 2009     Adequately                                                                  Yes                    Double Blinded                                                   No                    Yes                                                                      14.3%/9.3%                                                                             Yes

VS -- viscosupplementation; PLB -- placebo; ITT -- itention to treat.

Randomization schedules based on randomly permuted blocks were considered not adequately according to Cochrane Handbook 5.0.2 \[2008\];

All the studies declared double-blind intervention, adequate methods of which were decribed explictly; outcome assessors were also considered to be blinded;

Qvistgaard' study added lidocaine during injection equally in all groups;

Less than 25% loss-to-follow-up rate was considered acceptable.

###### 

Percentage changes from baseline of pain score in the included trials.

  Study             Outcomes                          Treatments     No. of patients   Baseline         \% Change from baseline at different time points                                                                          
  ----------------- --------------------------------- -------------- ----------------- ---------------- ------------------------------------------------------------ ------------------------------------------------------------ --------------------------------------------------------------------
  Atchia 2011       NRS pain (0--10)                  Durolane       19                6.2              NS                                                           NS                                                           NS
  Saline            19                                6.3            NS                NS               NS                                                                                                                        
  Brander 2018      WOMAC Pain score                  Hylan G-F 20   182               6.42±0.06        NA                                                           −27.6%^\*\*\*^                                               −34.4%^\*\*\*^
  Saline            175                               6.48±0.07      NA                −30.1%^\*\*\*^   −37.3%^\*\*\*^                                                                                                            
  Migliore 2009     Pain score (0--10 VAS)            Hyalubrix      22                6.4±1.94         NA                                                           NA                                                           −29.7%^\*\*^,[\#](#tfn10-medscimonit-25-6436){ref-type="table-fn"}
  Mepivacaine       20                                6.0±1.94       NA                NA               −16.7%^\*\*^                                                                                                              
  Qvistgaard 2006   Pain on walking (0--100 mm VAS)   Hyalgan        33                49.2±24.8        −20.3%[\*](#tfn9-medscimonit-25-6436){ref-type="table-fn"}   −22.4%[\*](#tfn9-medscimonit-25-6436){ref-type="table-fn"}   −22.4%[\*](#tfn9-medscimonit-25-6436){ref-type="table-fn"}
  Saline            36                                42.4±19.7      +4.7%             −2.4%            −11.8%                                                                                                                    
  Richette 2009     Pain score (0--100 mm VAS)        Adant          42                58.4±14.2        NA                                                           NA                                                           −13.4%
  Saline            43                                60.4±10.2      NA                NA               −15.1%                                                                                                                    

NRS -- numerical rating scale (0--10); NS -- not significant; WOMAC -- Western Ontario and McMaster Universities Arthritis Index; NA -- not available; VAS -- visual analogue scale.

Achieved statistical significance (^\*^ p\<0.05; ^\*\*^ p\<0.01; ^\*\*\*^ p\<0.001) compared to baseline;

achieved statistical significance (^\#^ p\<0.05; ^\#\#^ p\<0.01; ^\#\#\#^ p\<0.001) compared to placebo control.

###### 

Percentage changes from baseline of function score in the included trials.

  Study             Outcomes                 Treatments     No. of patients   Baseline         \% Change from baseline at different time points                    
  ----------------- ------------------------ -------------- ----------------- ---------------- -------------------------------------------------- ---------------- --------------------------------------------------------------------
  Atchia 2011       WOMAC Function score     Durolane       19                6                NS                                                 NS               NS
  Saline            19                       6              NS                NS               NS                                                                  
  Brander 2018      WOMAC Function score     Hylan G-F 20   182               6.33±0.09        NA                                                 −28.6%^\*\*\*^   −33.0%^\*\*\*^
  Saline            175                      6.44±0.08      NA                −28.4%^\*\*\*^   −33.1%^\*\*\*^                                                      
  Migliore 2009     Lequesne index           Hyalubrix      22                7.09±3.78        NA                                                 NA               −44.4%^\*\*^,[\#](#tfn13-medscimonit-25-6436){ref-type="table-fn"}
  Mepivacaine       20                       7.75±4.15      NA                NA               −17.2%^\*\*^                                                        
  Qvistgaard 2006   Lequesne index (1--24)   Hyalgan        33                10.0±4.0         NS                                                 NS               NS
  Saline            36                       9.5±3.8        NS                NS               NS                                                                  
  Richette 2009     WOMAC Function score     Adant          42                51.3±16.8        NA                                                 NA               −13.1%
  Saline            43                       49.7±13.4      NA                NA               −11.5%                                                              

NS -- not significant; WOMAC -- Western Ontario and McMaster Universities Arthritis Index; NA -- not available; VAS -- visual analogue scale.

Achieved statistical significance (^\*^ p\<0.05; ^\*\*^ p\<0.01; ^\*\*\*^ p\<0.001) compared to baseline;

achieved statistical significance (^\#^ p\<0.05; ^\#\#^ p\<0.01; ^\#\#\#^ p\<0.001) compared to placebo control.
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